A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073
This study is recruiting at 50 US sites in 23 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumors
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Incyte Corporation
- Last updated on ClinicalTrials.gov
- October 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alaska · 1
- Investigative Site US016 · Anchorage, AK
Arizona · 1
- Investigative Site US026 · Chandler, AZ
California · 7
- Investigative Site US051 · Duarte, CA
- Investigative Site US027 · Los Angeles, CA
- Investigative Site US036 · Los Angeles, CA
- Investigative Site US048 · Los Angeles, CA
- Investigative Site US049 · Orange, CA
- Investigative Site US034 · San Francisco, CA
- Investigative Site US001 · Santa Monica, CA
Colorado · 1
- Investigative Site US071 · Denver, CO
Florida · 4
- Investigative Site US072 · Fort Myers, FL
- Investigative Site US075 · Miami, FL
- Investigative Site US074 · St. Petersburg, FL
- Investigative Site US073 · West Palm Beach, FL
Georgia · 1
- Investigative Site US023 · Atlanta, GA
Illinois · 3
- Investigative Site US030 · Evanston, IL
- Investigative Site US005 · Naperville, IL
- Investigative Site US009 · Springfield, IL
Louisiana · 1
- Investigative Site US007 · New Orleans, LA
Massachusetts · 1
- Investigative Site US022 · Boston, MA
Michigan · 2
- Investigative Site US010 · Detroit, MI
- Investigative Site US078 · Grand Rapids, MI
Minnesota · 1
- Investigative Site US066 · Maple Grove, MN
New Jersey · 2
- Investigative Site US077 · Hackensack, NJ
- Investigative Site US017 · Morristown, NJ
New York · 5
- Investigative Site US059 · Lake Success, NY
- Investigative Site US003 · New York, NY
- Investigative Site US031 · New York, NY
- Investigative Site US041 · New York, NY
- Investigative Site US029 · The Bronx, NY
North Carolina · 1
- Investigative Site US035 · Chapel Hill, NC
Ohio · 2
- Investigative Site US020 · Cleveland, OH
- Investigative Site US050 · Cleveland, OH
Pennsylvania · 3
- Investigative Site US008 · Philadelphia, PA
- Investigative Site US043 · Philadelphia, PA
- Investigative Site US056 · Pittsburgh, PA
South Dakota · 1
- Investigative Site US055 · Sioux Falls, SD
Tennessee · 3
- Investigative Site US039 · Nashville, TN
- Investigative Site US060 · Nashville, TN
- Investigative Site US070 · Nashville, TN
Texas · 4
- Investigative Site US067 · Dallas, TX
- Investigative Site US062 · Denison, TX
- Investigative Site US011 · Houston, TX
- Investigative Site US063 · San Antonio, TX
Utah · 1
- Investigative Site US053 · Salt Lake City, UT
Virginia · 2
- Investigative Site US065 · Fairfax, VA
- Investigative Site US064 · Salem, VA
Washington · 2
- Investigative Site US081 · Olympia, WA
- Investigative Site US032 · Seattle, WA
Wisconsin · 1
- Investigative Site US044 · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.